Sharable link here: authors.elsevier.com/sd/article/S09…

Check out the latest from Balamurugan Sundaram, Nagakannan Pandian and team with Thirumala-Devi Kanneganti St. Jude Research, culminating a two decades-long search for NLRP12's trigger and downstream pathway! Out today Cell. Congrats to the team! 👏 Thread 👇 cell.com/cell/fulltext/…

A major congratulations to first authors Balamurugan Sundaram and Nagakannan Pandian and the team, Dr. Raghvendra Mall 🇮🇳🇧🇪🇶🇦🇺🇲🇦🇪👨‍💻, Yaqiu Wang, Roman Sarkar, Hee Jin Kim, Mrk Malireddi, raju karki, Laura Janke, Peter Vogel, and Thirumala-Devi Kanneganti, who dedicated countless hours to this project! 👏📷👏

Shareable link here: authors.elsevier.com/sd/article/S00…

दक्षिण भारतीय फिल्म ‘आदिपुरुष’मा समावेश ‘जानकी भारतीय छोरी हुन्’ भन्ने सब्द जबसम्म नेपालमा मात्र नभै भारतमा पनि सच्चिदैन तब सम्म काठमाडौ महानगर पालिका भित्र कुनै पनि हिन्दी फिल्म चल्न दिइने छैन । यो सच्याउन ३ दिनको समय दिइएको छ । माता सीताको जय होस ।

It's finally out! Well-done to Dr. Amy Chan and many others from Inflammasome Lab! Caspase-4 dimerisation and D289 auto-processing elicit an interleukin-1β-converting enzyme life-science-alliance.org/content/6/10/e…

Today Communications Biology: new work from first authors Mrk Malireddi and Ratnakar Bynigeri showing the utility of a #celldeath #CRISPR screen in innate #immune cells during #coronavirus infection to identify cell death molecules. Exciting #technique! St. Jude Research doi.org/10.1038/s42003…

Happening now: The inaugural CoE-III Symposium on innate immunity and #inflammation St. Jude Research with George Stark, Virginia Pascual, Dan Kastner, Judy Lieberman, Charles Dinarello @ProfPCDoherty Thirumala-Devi Kanneganti Prof. Hao Wu Schafer Lab. If you're on campus today, come to MTC!

😊 Thank you Clarivate for recognising the impact and influence of our research. It's an honour to be named one of the 7,125 Highly Cited Researchers in 2023. #HighlyCited2023 clarivate.com/highly-cited-r…

If you are attending the Inflammasome #Therapeutics Summit today in #Boston, come discuss inflammasome targeting beyond NLRP3 with Thirumala-Devi Kanneganti in Workshop A (8-10:30 AM EST). Looking forward to an exciting presentation and discussions about other inflammasome targets!

Looking forward to seeing everyone at the Inflammasome #Therapeutics Summit. It's a perfect time for this meeting, as the translational & therapeutic potential of targeting #inflammasomes continues to grow. Thirumala-Devi Kanneganti will be presenting at 11:30 AM EST today. See you there!

Check out the new TrendsTalk series Trends in Molecular Medicine, where Thirumala-Devi Kanneganti shares insights into being a researcher in #Memphis, and other leaders talk about the experience in their regions. What a great way to learn about #science around the #world! authors.elsevier.com/a/1iPGX5Eb1BZk…

Congratulations to the 2024 recipients of AAI Career Awardees for outstanding research and career achievements. The 2024 AAI Award winners will be recognized at IMMUNOLOGY2024™, May 3–7, in Chicago, Illinois. #AAI2024 #Immunology mailchi.mp/aai/aai-wins-a…

⭐⭐⭐ Check out our new paper published in Science Advances on the DNA sensor Ku70 in preventing bowel cancer (1/5) science.org/doi/10.1126/sc…

🤩 Another fascinating role of the membrane disruptor protein NINJ1 in disease, revealed by the Kanneganti Lab. Check this out 👇

Kanneganti Lab Clarivate raju karki Congrats Thirumala-Devi Kanneganti Kanneganti Lab ! 😍 Love it!

Just out in Nature Comms: acrolein promotes ferroptosis but blocks necroptosis, impairing chemo response. Blocking acrolein revives necroptosis + boosts anti-tumor immunity. 🔗 doi.org/10.1038/s41467… #CancerResearch #Ferroptosis #CellDeath

😊Delighted to share our latest #publication in collab with Dr. Rajendra Karki & colleagues from Seoul National University. In this Nature Communications paper, we show that #acrolein, a byproduct of our cells but also found in #cigarette smoke, #kills cells & contributes to #inflammation ourANU 1/3